Adamec Ivan, Mayer Miroslav, Ćorić Marijana, Ruška Berislav, Habek Mario
University Hospital Center Zagreb, Department of Neurology, Referral Center for Autonomic Nervous System Disorders, Zagreb, Croatia.
University Hospital Center Zagreb, Department of Internal Medicine, Division of Clinical Immunology and Rheumatology, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia.
Mult Scler Relat Disord. 2020 Nov;46:102589. doi: 10.1016/j.msard.2020.102589. Epub 2020 Oct 19.
Alemtuzumab is a humanized monoclonal antibody targeting CD52 protein that has shown great efficacy in the treatment of relapsing remitting multiple sclerosis and is associated with prolonged remission of the disease. Although it is highly effective, alemtuzumab can lead to serious adverse advents among which the most common are secondary autoimmune diseases. We present a patient who was treated with alemtuzumab for relapsing remitting multiple sclerosis. Her disease remained stable in a follow-up period of over ten years. However, during the follow-up period she developed thyroiditis one year, as well as systemic erythematous lupus seven years after the last alemtuzumab infusion, a disease not previously associated with alemtuzumab administration.
阿仑单抗是一种靶向CD52蛋白的人源化单克隆抗体，已显示出在复发缓解型多发性硬化症治疗中具有显著疗效，并与该疾病的长期缓解相关。尽管阿仑单抗非常有效，但它可导致严重的不良反应，其中最常见的是继发性自身免疫性疾病。我们报告一名接受阿仑单抗治疗复发缓解型多发性硬化症的患者。在超过十年的随访期内，她的病情保持稳定。然而，在随访期间，她在阿仑单抗输注一年后发生了甲状腺炎，在最后一次输注阿仑单抗七年之后出现了系统性红斑狼疮，这是一种以前未与阿仑单抗给药相关联的疾病。
